Clinical Trials

Examining the shift from transactional outsourcing to collaborative alliances, where shared risk and integrated data drive clinical success in the 2026 pharmaceutical landscape.

Daiichi Sankyo has formalised a strategic agreement with Tempus AI aimed at accelerating the clinical trajectory and differentiation of an antibody drug conjugate programme within oncology. The collaboration centres on integrating advanced AI capabilities into drug development workflows, with...

ICON, a world-leading clinical research organisation, has formalised a definitive partnership agreement with Advarra to introduce a new research-ready trial model designed to reshape how clinical trials are conducted. The collaboration brings together ICON’s global clinical trial solutions with...

Key Takeaways 80% of clinical trials experience enrolment delays and massive sunk costs with underperforming sites. Only 4% of US physicians participate in clinical research, leaving 96% of patients inaccessible under other HCPs’ care. Tokenization links Citeline’s proprietary data; specifically, 300+ million claims lives, 245+ million lab lives & 55 million+ EMR patient lives with 1.7+ million HCP national...

The UK government has announced nearly £50 million in funding aimed at strengthening the NHS’s capacity to conduct commercial research projects and clinical trials supported partly by the pharmaceutical industry. The investment is intended to supply critical research and...

Modern drug development necessitates a shift from fragmented data silos to a unified, intelligence-driven framework. Achieving global regulatory alignment requires a sophisticated approach to trial documentation standards and pharmaceutical regulatory governance, ensuring that clinical trial design remains robust across multiple jurisdictions. By leveraging standardized drug intelligence, sponsors can enhance submission readiness and maintain cross-border compliance, ultimately accelerating the delivery of life-saving therapies to patients worldwide.

Eli Lilly said that its weight-loss medicine Zepbound, when used in combination with psoriasis treatment Taltz, delivered stronger outcomes than Taltz alone in patients living with both psoriasis and obesity in a late-stage study. The psoriasis trial enrolled 274 patients...